JPRN-jRCT1030220320招募中未知
Development and exploration of an AI model to classify schizophrenia with signs of relapse and schizophrenia with no signs of relapse based on free conversations with medical staff
Toyoshiba Hiroyoshi0 个研究点目标入组 100 人开始时间: 2022年9月3日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- >= 18age old 至 <= 65age old（—）
- 性别
- All
入选标准
- •1) Outpatient
- •2)Between 18 and 65 years of age at the time of consent and diagnosed with schizophrenia according to the DSM-5.
- •3)Who can obtain written consent from the person
- •4)Who speak Japanese as his/her mother tongue and able to have an interview (conversation with doctors and medical staff)
排除标准
- •1)Who has been judged by a doctor to have difficulty in having conversation due to deafness, dysarthria, aphasia, etc.
- •2)Who has been diagnosed of having a pyschiatric disorder such as depression
- •3)Who has been diagnosed of a dementia or judged to have cognitive dysfunction due to neurological diseases (epilepsy, stroke, etc.)
- •4)Who has been judged by a doctor not to be suitable for this trial by any reasons
研究者
相似试验
已完成
不适用
Development and exploration of an AI model to classify healthy subject and suspected schizophrenia patient based on free conversations with medical staffSchizophreniaJPRN-jRCT1030210514Yuichiro Tsutsumi150
尚未招募
Unknown
Development of an Artificial Intelligence Model for Mask Ventilation Difficulty/Intubation Difficulty Classification Using Deep Learning with Patient Facial ImagesScheduled surgical casesJPRN-UMIN000052233Yamagata Universal Faculty of Medcine800
招募中
Unknown
Artificial Intelligence Predicts Refractory Septic Shock in Sepsis Patients: A Validated Model for Early predictioCTRI/2024/06/069604Mukkelli Vinay Gandhi
尚未招募
Unknown
Developing an Artificial intelligence system to identify anatomical structures in radiographsCTRI/2024/02/062448Vobilineni Vinathi Sai Subhanika
尚未招募
不适用
This study is trying to develop a computational model to find out which patients are likely to benefit from immune therapyCTRI/2022/11/047205Kerala Startup Mission